학술논문

Second-Line and Third-Line Therapy with Nanoliposomal Irinotecan (nal-IRI) in pancreatic cancer: A Single Center Experience
Document Type
Journal
Source
ONCOLOGY RESEARCH AND TREATMENT; NOV 2022, 45 SUPPL 3, p92-p92, 1p. Supplement: 3
Subject
Language
English
ISSN
22965262